EXOZ News & Events

eXoZymes files $50M mixed securities shelf

eXoZymes together with its spinout NCTx, announced additional numbers from their biomanufacturing breakthrough - achieving a purity higher than 99% in the initial lab scale validation that produced 4 grams of NCT. Co-founder and VP of Research, Dr. Tyler Korman, states, "Producing 4 grams of NCT at a purity higher than 99% is the kind of validation a novel platform like ours needs, to demonstrate the immense potential. Compared to extracting this from natural resources, which is the current way, you would need tens of kilograms of hemp seeds to produce the same quantity and then you'd have the headache of extracting it. That's obviously neither an effective nor sustainable approach, which is why our exozyme biosolutions are the perfect way forward - both for NCT as well as other naturally sourced compounds."

eXoZymes announced its role in the Meta-PURE initiative, a $9.2M National Science Foundation funded project under the CFIRE program aimed at transforming the scalability and accessibility of cell-free systems to expand real-world applications. Led by Georgia Tech with a coalition of academic and industry groups, Meta-PURE will build a suite of standardized, interoperable 'modules' for cell-free biomanufacturing, enabling plug-and-play modules that can rapidly shift between use cases - from high-value nutraceuticals, to essential chemicals or pharmaceuticals. eXoZymes' contribution builds on its ability to design complex enzyme cascades that operate outside of cells at unprecedented yields. "Our job in Meta-PURE is to build a cell-free power plant - an ATP-generating module that other teams can plug into to drive their own production modules," said Dr. Paul Opgenorth, co-founder of eXoZymes and co-principal investigator on the award. Dr. Opgenorth continues, "By decoupling the power module from the production module, we're enabling faster reaction times, greater product yields, and making the development of production modules more accessible for our partners across a broad spectrum of synthetic biology applications."

eXoZymes announced the appointment of Damien Perriman to a newly created role as chief commercial officer.